BioMarin Pharmaceutical Inc. (LON:0HNC)

Market Cap	10.30B
Revenue (ttm)	2.28B
Net Income (ttm)	340.96M
Shares Out	n/a
EPS (ttm)	1.77
PE Ratio	30.21
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	345
Average Volume	1,469
Open	68.77
Previous Close	68.92
Day's Range	68.25 - 70.11
52-Week Range	64.65 - 99.65
Beta	n/a
RSI	67.14
Earnings Date	Feb 21, 2025

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inher...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1996
• Employees: 3,401
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HNC

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD